Weekly Research Digest

February 2-6, 2026 | AI • Gene Therapy • Radioligand Theranostics

🤖 Artificial Intelligence

Open-Source AI Tool Beats Giant LLMs in Literature Reviews

Nature | February 3, 2026

Research Tool Researchers published the recipe for an AI model that reviews scientific literature more accurately than major commercial models, with particular excellence in citation accuracy. This open-source breakthrough addresses one of the most persistent challenges in AI-assisted research: hallucinated references and citation errors.

Read full article →

Apple-Google Gemini Partnership Reshapes AI Landscape

Multiple Sources | February 2026

Industry Apple announced a multiyear partnership integrating Google's Gemini models into Apple's foundation models to enhance Siri and Apple Intelligence features. The deal reflects Apple's strategic decision to leverage Google's advanced backbone models rather than develop every AI layer internally, potentially bringing deeper personalization to Apple devices while maintaining on-device processing and privacy standards.

Full legal and industry analysis →

Europe's AI Imperative: Blueprint for Global Tech Leadership

arXiv Preprint | February 15, 2026

Policy Following the AI Action Summit 2025 in Paris, European researchers published a strategic blueprint addressing Europe's position in the global AI race. The paper emphasizes convergence of AI with quantum computing, biotech, robotics, and high-performance computing as critical to maintaining geopolitical balance. Authors argue Europe must rethink its AI strategy to compete with US venture capital power and China's scale-oriented approach.

Read the blueprint →

Regulatory Update: EU AI Act Guidelines

The European Commission is drafting contingency guidelines to support compliance with high-risk AI systems under the AI Act, addressing delays in technical standards from CEN-CENELEC. These guidelines would act as a temporary bridge until industry standards materialize, with formal obligations potentially delayed to late 2027 or 2028.

White House: AI and The Great Divergence

White House Research | January 20, 2026

Policy The Trump administration released a position paper on laying groundwork for American AI dominance through accelerated innovation, infrastructure development, and strategic positioning. The document outlines how AI capabilities may create significant economic and technological divergences between nations.

Full White House statement →

🧬 Gene Therapy

Innovative CAR-T Destroys Cancer Without Dangerous Side Effects

Nature | February 3, 2026

Breakthrough A novel CAR-T therapy demonstrated selective tumor cell targeting in mice without suppressing the immune system or causing dangerous cytokine release syndrome. This represents a potential paradigm shift in CAR-T safety profiles, addressing one of the most significant barriers to broader clinical adoption.

Read the research →

Around the Helix: Latest Cell & Gene Therapy Updates

CGTLive | February 4, 2026

Clinical Updates Key Developments:

Ocugen's OCU410ST continues showing efficacy in Phase 1 Stargardt disease trial
Taysha's TSHA-102 dosed first patient in pivotal Phase 3 trial for Rett syndrome
Spur's avigbagene parvec (FLT201) showed rapid, sustained decreases in Gaucher disease biomarkers at 2 years
Wave Life Sciences regained full rights to WVE-006 RNA editing therapy for AATD from GSK
Anixa's CAR/CER-T therapy received USAN Council name "liraltagene autoleucel" for ovarian cancer program

Full company updates →

Ultragenyx UX111 Gene Therapy Shows Positive Long-Term Data

Yahoo Finance | February 5, 2026

FDA Submission Ultragenyx announced positive long-term clinical data for UX111, its AAV9 gene therapy for Sanfilippo syndrome type A, alongside FDA BLA resubmission with a targeted 6-month review. UX111 demonstrated clinically meaningful preservation and improvement of cognitive and motor function versus natural history, potentially shifting the investment narrative for this rare disease program.

Investment analysis →

CAR-T Therapy Transforms Autoimmune Disease Treatment

UNC Medicine | January 21, 2026

Phase 2b/3 A groundbreaking clinical trial featured in Nature Medicine's "Eleven Clinical Trials That Will Shape Medicine in 2026" shows mRNA-based CAR-T therapy achieving 57% minimal symptom expression in myasthenia gravis patients by month 6, with remission maintained through month 12. Treatment consists of six weekly outpatient infusions, with some participants remaining symptom-free over a year. This mRNA CAR-T platform may extend to lupus, rheumatoid arthritis, and multiple sclerosis.

Full trial details →

FDA Signals Flexible Approach for Autoimmune CAR-T Therapies

FierceBiotech | February 2, 2026

Regulatory FDA officials published perspective in Annals of Internal Medicine signaling willingness to support autoimmune CAR-T development with flexible regulatory approach. While recognizing potential for durable, drug-free remission, FDA remains cautious about unpredictable long-term toxicity. Kyverna Therapeutics' miv-cel for stiff person syndrome targets FDA application in first half 2026, potentially becoming first approved CAR-T for autoimmune disease.

FDA perspective analysis →

⚠️ Clinical Hold Alert

REGENXBIO Gene Therapy Trials Halted: FDA paused trials for two experimental gene therapies from REGENXBIO (RGX-121 for MPS II and related programs) after one child developed a brain tumor. The company is working with FDA to address safety concerns. (STAT News, January 27, 2026)

☢️ Radioligand Theranostics

FDA Approves Pluvicto for Earlier Use Before Chemotherapy

Novartis | March 27, 2025 (Recent Major Milestone)

FDA Approval FDA approved Novartis' Pluvicto (lutetium-177-PSMA-617) for earlier use in PSMA-positive metastatic castration-resistant prostate cancer before chemotherapy. Based on two Phase III studies (VISION and PSMAfore), Pluvicto is the only PSMA-targeted agent proven to significantly improve radiographic progression-free survival with demonstrated tolerability in both pre- and post-taxane settings. This approval dramatically expands the patient population eligible for PSMA radioligand therapy.

Official FDA approval →

AACR 2026: Multiple PSMA RLT Resistance Mechanisms Identified

Cancer Research | January 19, 2026

Basic Science American Association for Cancer Research presentations revealed critical insights into PSMA radioligand therapy resistance:

Lead-212 (²¹²Pb) Alpha Emitter: Novel ADVC001 shows potent cytotoxic activity with EC50 of 2.7-7.2 kBq/mL across PSMA-expressing cell lines (Abstract B041)
Spatial Heterogeneity: SHAPE cohort study integrating PET, histopathology, spatial transcriptomics shows RLT-treated tumors exhibit copy-number-dominant profile vs untreated (Abstract PR027)
PI3K Pathway Crosstalk: PSMA-PI3K signaling heterogeneity contributes to Lu-PSMA resistance; CTC profiling reveals inter-patient variability (Abstract B073)
Genomic Predictors: AR amplification, PTEN loss, and HRR alterations associated with shorter PFS and OS; composite molecular risk stratification validated (Abstract B057)

PSMA Radioligand + SBRT Doubles Progression-Free Interval

UCLA Health | November 11, 2025 (Recent Landmark)

Randomized Trial First randomized trial showing PSMA-targeting radioligand significantly delays progression when added to stereotactic body radiotherapy (SBRT). Patients with recurring prostate cancer went more than twice as long without disease worsening compared to SBRT alone. This combination gives patients extended time before needing hormonal therapy, avoiding significant side effects like fatigue and bone loss.

Read UCLA research →

Terbium-161 Shows Superior Tumor Dosimetry vs Lutetium-177

PubMed Central | February 23, 2024 (Continued Relevance)

Dosimetry Intra-individual head-to-head pilot study demonstrates [¹⁶¹Tb]Tb-PSMA-617 delivered higher tumor-absorbed doses and superior therapeutic index compared to [¹⁷⁷Lu]Lu-PSMA-617 in mCRPC patients. Terbium-161 emits additional Auger and conversion electrons, providing advantages over standard lutetium-177. This preliminary data supports ¹⁶¹Tb as promising next-generation radionuclide for PSMA-RLT.

Full dosimetry study →

Theranostics Pipeline: Nearly 90 Products in Early-Stage Trials

PubMed Central | July 26, 2025 (Recent Review)

Pipeline Analysis Comprehensive review of theranostics and oncology PET reveals explosive growth: nearly 90 products in phase 1/2 trials with over 500 total studies underway. Alpha emitters like ²¹¹At showing preliminary efficacy in radioiodine-refractory thyroid cancer. Novel pan-tumor targets (TROP-2, Nectin-4, LAT1, GPC-1, EphA2) under development with clinical translation anticipated. Artificial intelligence optimizing image reconstruction for enhanced spatial/temporal resolution.

Read comprehensive review →

Active Clinical Trials	Status	Key Focus
FLEX-MRT Phase 2 Flexible Dosing	Recruiting	Extended ¹⁷⁷Lu-PSMA-617 up to 12 cycles vs standard 6 cycles; targeting 2-year survival improvement
Bullseye Trial NCT04443062	Active	¹⁷⁷Lu-PSMA-617 in oligo-metastatic hormone-sensitive prostate cancer (≤5 metastases) pre-castration resistance
LUDOPATH NCT07370597	New Jan 2026	¹⁷⁷Lu dosimetry as predictive biomarker of response in mCRPC patients
PSMAddition NCT04720157	Ongoing	Moving Pluvicto into first-line settings for metastatic prostate cancer
LUNAR Trial NCT05496959	Emerging Data	Radioligand therapy + stereotactic radiation potentially replacing hormonal therapy

📌 In Case You Missed It: Recent Milestones Still Shaping the Field

REGENXBIO Duchenne Gene Therapy: 18-Month Functional Data

PRNewswire | January 10, 2026

Pivotal Data RGX-202 Phase I/II functional data at pivotal dose demonstrates long-term, durable treatment effect at 18 months. All patients (n=4) exceeded expected disease trajectory on North Star Ambulatory Assessment using cTAP model, improving average 7.4 points vs cTAP. REGENXBIO expects pivotal topline data in early Q2 2026 and BLA submission mid-2026. Company also anticipates FDA PDUFA decision for clemidsogene lanparvovec (RGX-121) for MPS II on February 8, 2026, which would include Priority Review Voucher.

Full investor update →

Cell & Gene Therapy Market Snapshot

Yahoo Finance | February 5, 2026

By the Numbers:

$1.2B in Zolgensma (SMA gene therapy) sales
$1.5B Yescarta (CAR-T) revenue
46 FDA-approved cell and gene therapies
$2B+ in strategic partnership deals

The field continues exponential commercial growth while maintaining robust clinical development pipelines.

Expert Commentary: Clinical Implementation Workflow

PSMA PET/CT Integration Best Practices:

Patient Selection: PSMA PET required for therapy eligibility; minimum SUVmax thresholds vary by protocol but typically >liver uptake
Dosimetry Planning: Baseline imaging for absorbed dose calculations becoming standard; personalized dosing under investigation
Response Assessment: PSA decline ≥50% at 12 weeks strong prognostic marker; PSA reduction ≥30% at 6 weeks predicts OS (16.7 vs 6.5 months)
Resistance Monitoring: Serial CTC profiling and liquid biopsy cfDNA tracking genomic evolution (AR amplification, PTEN loss, HRR alterations)
Combination Strategies: Active trials combining RLT with ARPI, PARP inhibitors, and immune checkpoint inhibitors